Eiger BioPharmaceuticals (STU:72C) Days Payable: 2,997.42 (As of Dec. 2023)

What is Eiger BioPharmaceuticals Days Payable?

Eiger BioPharmaceuticals STU:72C 10 Days Payable is 2,997.42 as of Dec. 2023. GuruFocus rates STU:72C with a GF Score™ of 10/100.

Eiger BioPharmaceuticals's average Accounts Payable for the six months ended in Dec. 2023 was €3.25 Mil. Eiger BioPharmaceuticals's Cost of Goods Sold for the six months ended in Dec. 2023 was €0.20 Mil. Hence, Eiger BioPharmaceuticals's Days Payable for the six months ended in Dec. 2023 was 2,997.42.

The historical rank and industry rank for Eiger BioPharmaceuticals's Days Payable or its related term are showing as below:

STU:72C's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 112.83
* Ranked among companies with meaningful Days Payable only.

Eiger BioPharmaceuticals's Days Payable increased from Dec. 2022 (1,096.47) to Dec. 2023 (2,997.42). It may suggest that Eiger BioPharmaceuticals delayed paying its suppliers.

Eiger BioPharmaceuticals Days Payable Related Terms

Eiger BioPharmaceuticals Days Payable Historical Data

* Premium members only.

The historical data trend for Eiger BioPharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eiger BioPharmaceuticals Days Payable Chart

Eiger BioPharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

0.00

2,954.84

1,614.93

86,363.98

Eiger BioPharmaceuticals Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Days Payable	Get a 7-Day Free Trial															6,014.37	1,096.47	0.00	2,997.42	8,998.91

STU:72C vs EDSA, SIGY, EVLO: Days Payable Comparison

For the Biotechnology subindustry, Eiger BioPharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eiger BioPharmaceuticals Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eiger BioPharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Eiger BioPharmaceuticals's Days Payable falls into.

Save Embed

10GF Score

Eiger BioPharmaceuticals Inc STU:72C

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Eiger BioPharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Eiger BioPharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (8.472	+	1.939)	/	2 )	/	0.022	*	365
=	5.2055					/	0.022	*	365
=	86,363.98

Eiger BioPharmaceuticals's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (4.565	+	1.939)	/	2 )	/	0.198	*	365 / 2
=	3.252					/	0.198	*	365 / 2
=	2,997.42

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 2,997.42 mean?

Eiger BioPharmaceuticals (STU:72C) has a Days Payable of 2,997.42 as of Dec. 2023. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Eiger BioPharmaceuticals and its competitors.

Is Eiger BioPharmaceuticals' Days Payable too high?

Eiger BioPharmaceuticals' current Days Payable is 2,997.42. The Biotechnology industry median Days Payable is 112.83. Eiger BioPharmaceuticals' value of 2,997.42 is 2556.6% above this industry median. Overall, Eiger BioPharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.

How does Eiger BioPharmaceuticals' Days Payable compare to EDSA and SIGY?

Eiger BioPharmaceuticals' Days Payable of 2,997.42 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 112.83. Eiger BioPharmaceuticals' value of 2,997.42 is 2556.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 112.83, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eiger BioPharmaceuticals's current Days Payable of 2,997.42 is 2556.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Eiger BioPharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 112.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eiger BioPharmaceuticals's current Days Payable is 2,997.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Eiger BioPharmaceuticals stock overvalued right now?

Eiger BioPharmaceuticals (STU:72C) has a current Days Payable of 2,997.42. The current Days Payable is 2,997.42 and 2556.6% above the Biotechnology industry median of 112.83. Eiger BioPharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Eiger BioPharmaceuticals (STU:72C), the current Days Payable is 2,997.42 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eiger BioPharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies EDSA SIGY EVLO GTBP IMNN NHWK TMBR GRTX CMRA ONVO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address 2155 Park Boulevard, Palo Alto, CA, USA, 94306

Website https://www.eigerbio.com

Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

10GF Score

Get the complete analysis for STU:72C

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.18

Price

View STU:72C Analysis

See Days Payable data for all stocks →